Author

B. Lowenberg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:host-pathogen & immune response· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1

Frequent Co-Authors

H. Altmann· 2 shared J. F. DiPersio· 2 shared J. K. Davidson-Moncada· 2 shared J. Muth· 2 shared J. Vadakekolathu· 2 shared M. Bornhauser· 2 shared S. E. Church· 2 shared S. Reeder· 2 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

H. Altmann

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Deconvolution Of Hematopoietic Stem/Progenitor Cell Signaling Predicts Inflammatory Niche Remodeling To Be A Determinant Of Tissue Failure And Outcome In Human AML

L. Chen, E. Pronk, C. van Dijk, Y. Bian, J. Feyen, T. van Tienhoven, M. Yildirim, P. Pisterzi, M. de Jong, A. Bastidas, R. Hoogenboezem, C. Wevers, E. Bindels, B. Lowenberg, T. Cupedo, , M. Raaijmakers

The paper uses scRNA-seq to analyze signaling between hematopoietic stem/progenitor cells and their niches in AML, identifying inflammatory niche remodeling as a factor affecting tissue failure and patient outcome.

bioRxiv · May 5, 2023 · PreprintCancer Biology

TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

C. Lai, J. Vadakekolathu, S. Reeder, S. E. Church, T. Hood, I. Aldoss, J. Godwin, M. J. Wieduwilt, M. Arellano, J. Muth, F. Ravandi, K. Sweet, H. Altmann, G. A. Foulds, F. Stolzel, , S. Rutella

This paper shows TP53 mutations in AML are linked to immune features and improved response to flotetuzumab immunotherapy.

bioRxiv · Feb 28, 2020 · PreprintImmunology

Immune Landscapes Predict Chemotherapy Resistance And Immunotherapy Response In Acute Myeloid Leukemia

J. Vadakekolathu, M. D. Minden, T. Hood, S. E. Church, S. Reeder, H. Altmann, A. H. Sullivan, E. J. Viboch, T. Patel, N. Ibrahimova, S. E. Warren, A. Arruda, Y. Liang, J. Muth, M. Schmitz, , S. Rutella

This study identifies immune subtypes in AML and shows that IFN-gamma profiles predict chemotherapy resistance and immunotherapy response.

bioRxiv · Jul 26, 2019Immunology